Top

Published in:

01-06-2013 | Neurology and Preclinical Neurological Studies - Original Article

A therapeutic approach to cerebrovascular diseases based on indole substituted hydrazides and hydrazines able to interact with human vascular adhesion protein-1, monoamine oxidases (A and B), AChE and BuChE

Authors: Gerard Esteban, Irene Bolea, Ping Sun, Montse Solé, Abdelouahid Samadi, José Marco-Contelles, Mercedes Unzeta

Published in: Journal of Neural Transmission | Issue 6/2013

Abstract

Herein, we report the biological evaluation of a series of indole substituted hydrazides and hydrazines throughout the assessment of their multipotent inhibitory potency towards monoamine oxidase (MAO) A and B, semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1), and the cholinesterases, acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). Hydrazine JL72 (3-(3-hydrazinylpropyl)-1H-indole) showed a potent, reversible and non-time-dependent inhibition of MAO-A, which suggests its capacity in restoring serotoninergic neurotransmission being devoid of the side effects observed for classic MAO-A inhibitors. In addition, JL72 behaved as a moderate BuChE inhibitor. Finally, both hydrazines and hydrazides derivatives showed high affinity towards SSAO/VAP-1. Among them, JL72 behaved as a noncompetitive and the most potent inhibitor (IC₅₀ = 0.19 ± 0.04 μM), possessing also a significant anti-inflammatory activity. The combined inhibition of SSAO/VAP-1, MAO (A and B), AChE and BuChE appear as an important therapeutic target to be considered in the treatment of cerebrovascular and neurological disorders such as Alzheimer’s disease.

Alemany A, Bernabé M, Elorriaga C, Fernández-Alvarez E, Lora-Tamayo M, Nieto O (1966) Potential psychotropic agents. I. Synthesis of 1-(2-indolylcarbonyl)-2-alkylhydrazines, 1-(3-indolylcarbonyl)-2-alkylhydrazines and 1-(3-indolylacetyl)-2-alkylhydrazines, and measurement, in vitro, of their monoamine oxidase inhibitory activity. Bull Soc Chim Fr 8:2486–2497PubMed

Alemany A, Fernández-Álvarez E, Hernández-Sánchez M (1975) Enzyme inhibitors. X. Preparation and in vitro study of N2-substituted 2-(N-methylindolyl) and 2-(N- benzylindolyl) carbohydrazides as monoamineoxidase inhibitors. An Quím 71:406–411

Bernabé M, Fernández-Álvarez E, Lora-Tamayo M, Nieto O (1971) Potential psychotropic drugs. V. Monoamine oxidase inhibitors. Preparation and study of some indolyl-3 alkyl-hydrazines. Bull Soc Chim Fr 5:1882–1887PubMed

Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254PubMedCrossRef

Castro A, Martínez A (2006) Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr Pharm Des 12:4377–4387PubMedCrossRef

Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 2:1403PubMedCrossRef

Deane R, Wu Z, Sagare A, Davis J, Du YS, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43:333–344PubMedCrossRef

Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95PubMedCrossRef

Ferrer I, Lizcano JM, Hernández M, Unzeta M (2002) Overexpression of semicarbazide sensitive amine oxidase in the cerebral blood vessels in patients with Alzheimer’s disease and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Neurosci Lett 321:21–24PubMedCrossRef

Fowler CJ, Tipton KF (1981) Concentration dependence of the oxidation of tyramine by the two forms of rat liver mitochondrial monoamine oxidase. Biochem Pharmacol 30:3329–3332PubMedCrossRef

Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, Chen CP, Francis PT, Lasheras B, Ramirez MJ (2005) Cholinergic-serotoninergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer’s disease. Neuropsychologia 43:442–449PubMedCrossRef

Geula C, Mesulam MM (1999) Cholinergic systems in Alzheimer’s disease. In: Terry RD, Katzman R, Bick K, Sisodia SS (eds) Alzheimer disease, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, PA, pp 69–292

Goedert M, Spillantini MG (2006) A century of Alzheimer’s disease. Science 314:777–781PubMedCrossRef

Gomez N, Unzeta M, Tipton KF, Anderson MC, O’Carroll AM (1986) Determination of monoamine oxidase concentrations in rat liver by inhibitor binding. Biochem Pharmacol 35:4467–4472PubMedCrossRef

Hernandez-Guillamon M, Garcia-Bonilla L, Solé M, Sosti V, Parés M, Campos M, Ortega-Aznar A, Domínguez C, Rubiera M, Ribó M, Quintana M, Molina CA, Alvarez-Sabín J, Rosell A, Unzeta M, Montaner J (2010) Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke. Stroke 41:1528–1535PubMedCrossRef

Hernandez-Guillamon M, Solé M, Delgado P, García-Bonilla L, Giralt D, Boada C, Penalba A, García S, Flores A, Ribó M, Alvarez-Sabin J, Ortega-Aznar A, Unzeta M, Montaner J (2012) VAP-1/SSAO plasma activity and brain expression in human hemorrhagic stroke. Cerebrovasc Dis 33:55–63PubMedCrossRef

Jalkanen S, Salmi M (2008) VAP-1 and CD73, endothelial cell surface enzymes in leukocyte extravasation. Arterioscler Thromb Vasc Biol 28:18–26PubMedCrossRef

Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17:1285–1297PubMedCrossRef

Koskinen K, Vainio PJ, Smith DJ, Pihlavisto M, Ylä-Herttuala S, Jalkanen S, Salmi M (2004) Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1). Blood 103:3388–3395PubMedCrossRef

Lizcano JM, Fernández de Arriba A, Tipton KF, Unzeta M (1996) Inhibition of bovine lung semicarbazide-sensitive amine oxidase (SSAO) by some hydrazine derivatives. Biochem Pharmacol 52:187–195PubMedCrossRef

Monge A, Palop JA, Goni T, Martinez A, Fernandez-Alvarez E (1985) About the synthesis of (1,2) diazepinoindole derivatives from ethyl 2-(1-methylindole)acetate, 2-indole- and 3-indoleacetohydrazones. J Heterocyclic Chem 22:1445–1451CrossRef

Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63PubMedCrossRef

Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE (1977) Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 34:247–265PubMedCrossRef

Salmi M, Kalimo K, Jalkanen S (1993) Induction and function of vascular adhesion protein-1 at sites of inflammation. J Exp Med 178:2255–2260PubMedCrossRef

Solé M, Unzeta M (2011) Vascular cell lines expressing SSAO/VAP-1: a new experimental tool to study its involvement in vascular diseases. Biol Cell 103:543–557PubMedCrossRef

Song MS, Baker GB, Dursun SM, Todd KG (2010) The antidepressant phenelzine protects neurons and astrocytes against formaldehyde-induced toxicity. J Neurochem 114:1405–1413PubMed

Terry AV Jr, Buccafusco JJ, Wilson C (2008) Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets. Behav Brain Res 195:30–38PubMedCrossRef

Vinters HV, Pardridge WM, Secor DL, Ishii N (1988) Immunohistochemical study of cerebral amyloid angiopathy. II. Enhancement of immunostaining using formic acid pretreatment of tissue sections. Am J Pathol 133:150–162PubMed

Wood PL, Khan MA, Moskal JR, Todd KG, Tanay VA, Baker G (2006) Aldehyde load in ischemia-reperfusion brain injury: neuroprotection by neutralization of recative aldehydes with phenelzine. Brain Res 1122:184–190PubMedCrossRef

Zlokovic BV (2005) Neurovascular mechanisms of Alzheimer’s neurodegeneration. Trends Neurosci 28:202–208PubMedCrossRef

Title: A therapeutic approach to cerebrovascular diseases based on indole substituted hydrazides and hydrazines able to interact with human vascular adhesion protein-1, monoamine oxidases (A and B), AChE and BuChE
Authors: Gerard Esteban
Irene Bolea
Ping Sun
Montse Solé
Abdelouahid Samadi
José Marco-Contelles
Mercedes Unzeta
Publication date: 01-06-2013
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 6/2013
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-012-0949-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A therapeutic approach to cerebrovascular diseases based on indole substituted hydrazides and hydrazines able to interact with human vascular adhesion protein-1, monoamine oxidases (A and B), AChE and BuChE

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2013

Do MAO A and MAO B utilize the same mechanism for the C–H bond cleavage step in catalysis? Evidence suggesting differing mechanisms

Study on SSAO enzyme activity and anti-inflammatory effect of SSAO inhibitors in animal model of inflammation

Insights into the binding mode of new N-substituted pyrazoline derivatives to MAO-A: docking and quantum chemical calculations

Characterization of diamine oxidase from human seminal plasma

Special Issue: 15th amine oxidase conference: re-examine the amines

In silico identification of novel and selective monoamine oxidase B inhibitors